1. Home
  2. BCAL vs ABUS Comparison

BCAL vs ABUS Comparison

Compare BCAL & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern California Bancorp

BCAL

Southern California Bancorp

HOLD

Current Price

$21.86

Market Cap

704.1M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.35

Market Cap

836.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCAL
ABUS
Founded
2001
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
704.1M
836.0M
IPO Year
2020
2008

Fundamental Metrics

Financial Performance
Metric
BCAL
ABUS
Price
$21.86
$4.35
Analyst Decision
Buy
Analyst Count
4
0
Target Price
★ $24.75
N/A
AVG Volume (30 Days)
187.5K
★ 6.3M
Earning Date
10-30-2026
11-12-2026
Dividend Yield
★ 2.22%
N/A
EPS Growth
★ 777.27
55.26
EPS
★ 0.86
0.84
Revenue
N/A
★ $14,083,000.00
Revenue This Year
$1.36
$1,208.75
Revenue Next Year
$6.48
N/A
P/E Ratio
$25.20
★ $4.98
Revenue Growth
N/A
★ 128.21
52 Week Low
$16.61
$3.50
52 Week High
$22.41
$5.45

Technical Indicators

Market Signals
Indicator
BCAL
ABUS
Relative Strength Index (RSI) 52.76 35.56
Support Level $20.52 $4.17
Resistance Level $21.87 $4.57
Average True Range (ATR) 0.40 0.18
MACD 0.01 -0.02
Stochastic Oscillator 68.57 15.43

Price Performance

Historical Comparison
BCAL
ABUS

About BCAL Southern California Bancorp

California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: